FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1964507882> ?p ?o ?g. }

• W1964507882 endingPage "808" @default.
• W1964507882 startingPage "799" @default.
• W1964507882 abstract "Epstein-Barr virus (EBV) causes lymphomas in immunocompromised individuals such as recipients of stem cell or organ transplants and patients with acquired immunodeficiency syndrome (AIDS). EBV has also been detected in the Reed-Sternberg cells of approximately 50% of all cases of Hodgkin's disease (HD). The purpose of this study was to examine the safety, and the clinical and immunological effects of infusing allogeneic EBV-specific cytotoxic T lymphocytes (CTL) for patients with refractory EBV-positive malignancies. In this pilot study, we have treated four patients with EBV-related lymphoma using allogeneic EBV-specific CTL. Two patients received EBV-specific CTL derived from partially human leucocyte antigen (HLA)-matched donors and the other two from HLA-matched siblings. No complications were observed as a result of the CTL infusions and all patients showed increased levels of EBV-specific CTL precursors (CTLp) post infusion. Of the two organ transplant patients, one had refractory disease and has sustained a complete remission following the T-cell infusions. The second has also been disease free since T-cell infusions, although the efficacy cannot be definitively attributed to CTL therapy because this patient received local radiation therapy prior to immunotherapy. A patient with AIDS-related, EBV-positive lymphoma had disease progression following CTL infusions. One HD patient received HLA 4/6 matched T cells from an unrelated donor and showed a decrease in the size of affected lymph nodes and resolution of B-symptoms post infusion. In conclusion, adoptive immunotherapy with allogeneic EBV-specific CTL is safe and may have efficacy in patients with high-risk or refractory EBV-related tumours." @default.
• W1964507882 created "2016-06-24" @default.
• W1964507882 creator A5002305391 @default.
• W1964507882 creator A5004088608 @default.
• W1964507882 creator A5067774170 @default.
• W1964507882 creator A5074054433 @default.
• W1964507882 date "2002-08-15" @default.
• W1964507882 modified "2023-10-17" @default.
• W1964507882 title "Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma" @default.
• W1964507882 cites W1426751272 @default.
• W1964507882 cites W1484271079 @default.
• W1964507882 cites W150741373 @default.
• W1964507882 cites W151068973 @default.
• W1964507882 cites W166453000 @default.
• W1964507882 cites W1963705060 @default.
• W1964507882 cites W1977635228 @default.
• W1964507882 cites W1994652359 @default.
• W1964507882 cites W2005124378 @default.
• W1964507882 cites W2009844134 @default.
• W1964507882 cites W2017308991 @default.
• W1964507882 cites W2020696505 @default.
• W1964507882 cites W2026689623 @default.
• W1964507882 cites W2028475115 @default.
• W1964507882 cites W2032458486 @default.
• W1964507882 cites W2043307123 @default.
• W1964507882 cites W2050069240 @default.
• W1964507882 cites W2071015072 @default.
• W1964507882 cites W2078306979 @default.
• W1964507882 cites W2091022862 @default.
• W1964507882 cites W2112016055 @default.
• W1964507882 cites W2116187825 @default.
• W1964507882 cites W2137858837 @default.
• W1964507882 cites W2139033805 @default.
• W1964507882 cites W2150628430 @default.
• W1964507882 cites W2168750246 @default.
• W1964507882 cites W2175132952 @default.
• W1964507882 cites W2254901991 @default.
• W1964507882 cites W2257321319 @default.
• W1964507882 cites W2286687528 @default.
• W1964507882 cites W2300431937 @default.
• W1964507882 cites W2329058715 @default.
• W1964507882 cites W2332905513 @default.
• W1964507882 cites W2341259055 @default.
• W1964507882 cites W240565811 @default.
• W1964507882 cites W2413882182 @default.
• W1964507882 cites W260582458 @default.
• W1964507882 cites W315543599 @default.
• W1964507882 cites W51893192 @default.
• W1964507882 cites W98617215 @default.
• W1964507882 doi "https://doi.org/10.1046/j.1365-2141.2002.03683.x" @default.
• W1964507882 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12181048" @default.
• W1964507882 hasPublicationYear "2002" @default.
• W1964507882 type Work @default.
• W1964507882 sameAs 1964507882 @default.
• W1964507882 citedByCount "72" @default.
• W1964507882 countsByYear W19645078822012 @default.
• W1964507882 countsByYear W19645078822013 @default.
• W1964507882 countsByYear W19645078822014 @default.
• W1964507882 countsByYear W19645078822015 @default.
• W1964507882 countsByYear W19645078822016 @default.
• W1964507882 countsByYear W19645078822017 @default.
• W1964507882 countsByYear W19645078822018 @default.
• W1964507882 countsByYear W19645078822019 @default.
• W1964507882 countsByYear W19645078822020 @default.
• W1964507882 countsByYear W19645078822021 @default.
• W1964507882 countsByYear W19645078822022 @default.
• W1964507882 countsByYear W19645078822023 @default.
• W1964507882 crossrefType "journal-article" @default.
• W1964507882 hasAuthorship W1964507882A5002305391 @default.
• W1964507882 hasAuthorship W1964507882A5004088608 @default.
• W1964507882 hasAuthorship W1964507882A5067774170 @default.
• W1964507882 hasAuthorship W1964507882A5074054433 @default.
• W1964507882 hasConcept C147483822 @default.
• W1964507882 hasConcept C147969180 @default.
• W1964507882 hasConcept C154317977 @default.
• W1964507882 hasConcept C167672396 @default.
• W1964507882 hasConcept C202751555 @default.
• W1964507882 hasConcept C203014093 @default.
• W1964507882 hasConcept C2522874641 @default.
• W1964507882 hasConcept C2777701055 @default.
• W1964507882 hasConcept C2779338263 @default.
• W1964507882 hasConcept C2781375147 @default.
• W1964507882 hasConcept C55493867 @default.
• W1964507882 hasConcept C71924100 @default.
• W1964507882 hasConcept C86803240 @default.
• W1964507882 hasConcept C8891405 @default.
• W1964507882 hasConceptScore W1964507882C147483822 @default.
• W1964507882 hasConceptScore W1964507882C147969180 @default.
• W1964507882 hasConceptScore W1964507882C154317977 @default.
• W1964507882 hasConceptScore W1964507882C167672396 @default.
• W1964507882 hasConceptScore W1964507882C202751555 @default.
• W1964507882 hasConceptScore W1964507882C203014093 @default.
• W1964507882 hasConceptScore W1964507882C2522874641 @default.
• W1964507882 hasConceptScore W1964507882C2777701055 @default.
• W1964507882 hasConceptScore W1964507882C2779338263 @default.
• W1964507882 hasConceptScore W1964507882C2781375147 @default.
• W1964507882 hasConceptScore W1964507882C55493867 @default.
• W1964507882 hasConceptScore W1964507882C71924100 @default.

• next